First-line nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) in patients (pts) with unresectable malignant pleural mesothelioma (uMPM): 4-year update from CheckMate 743

G. Zalcman, Y. Oulkhouir, R. Cornelissen, L. Greillier, J. R. Rodriguez Cid, J. Mazieres, P. Briggs, A. K. Nowak, A. Tsao, N. Fujimoto, S. Peters, A. S. Mansfield, S. Popat, A. Nassar, J. Bushong, N. Hu, T. Spires, D. Balli, L. Eccles, P. Baas

Research output: Contribution to journalAbstract/Meeting Abstractpeer-review

3 Citations (Web of Science)
Original languageEnglish
Pages (from-to)S1438-S1439
Number of pages2
JournalAnnals of Oncology
Issue number7
Publication statusPublished - Sept 2022
Event2022 Annual Meeting of the European-Society-for-Medical-Oncology - , France
Duration: 9 Sept 202213 Sept 2022

Cite this